New drug combo takes on tough pancreatic cancer
Disease control
Recruiting now
This early-phase trial tests a new drug called GP-2250 combined with the chemotherapy gemcitabine in people with advanced pancreatic cancer that has worsened after standard treatment. The main goal is to check safety and find the right dose. About 64 adults will take part, and re…
Phase: PHASE1 • Sponsor: Persevere Therapeutics Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC